Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDA) is characterized by abundant infiltration of tumor-associated macrophages (TAMs). TAMs have been reported to drive resistance to gemcitabine, a frontline chemotherapy in PDA, though the mechanism of this resistance remains unclear. Profiling metabolite exchange...

Full description

Saved in:

Bibliographic Details
Published in:	Cell metabolism Vol. 29; no. 6; p. 1390
Main Authors:	Halbrook, Christopher J, Pontious, Corbin, Kovalenko, Ilya, Lapienyte, Laura, Dreyer, Stephan, Lee, Ho-Joon, Thurston, Galloway, Zhang, Yaqing, Lazarus, Jenny, Sajjakulnukit, Peter, Hong, Hanna S, Kremer, Daniel M, Nelson, Barbara S, Kemp, Samantha, Zhang, Li, Chang, David, Biankin, Andrew, Shi, Jiaqi, Frankel, Timothy L, Crawford, Howard C, Morton, Jennifer P, Pasca di Magliano, Marina, Lyssiotis, Costas A
Format:	Journal Article
Language:	English
Published:	United States 04.06.2019
Subjects:	Animals Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Cells, Cultured Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug Resistance, Neoplasm - drug effects Female Gemcitabine Humans Macrophages - metabolism Male Mice Mice, Inbred C57BL Mice, Transgenic Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pyrimidines - metabolism Pyrimidines - pharmacology RAW 264.7 Cells Xenograft Model Antitumor Assays pancreatic cancer deoxycytidine gemcitabine resistance immunometabolism metabolomics macrophage tumor-associated macrophage tumor microenvironment metabolic crosstalk pancreatic ductal adenocarcinoma
ISSN:	1932-7420, 1932-7420
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!